WHO ICTRP trial
A 14 week study where each subject takes 3 medicines (each for 2 weeks) being…
EUCTR2011-005914-12-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2011-005914-12-DE |
|---|---|
| Public title | A 14 week study where each subject takes 3 medicines (each for 2 weeks) being developed to treat COPD |
| Scientific title | A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) |
| Primary sponsor | GlaxoSmithKline Research & Development Limited |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Estonia;Germany |
| Conditions | Chronic Obstructive Pulmonary Disease (COPD) MedDRA version: 15.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C]… |
| Interventions | Product Name: Umeclidinium/Vilanterol Product Code: GSK573719/GW642444 Pharmaceutical Form: Inhalation powder, pre-dispensed INN or Proposed INN: Umeclidinium Current Sponsor code: GSK573719 Concentration unit: µg microgram(s) Concentration… |
| Registration date | May 6, 2012 |
| Target size | 210 |
| Secondary IDs | DB2116133 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: